Difference between revisions of "Etoposide (Vepesid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - ": new" to ": New")
m
Line 68: Line 68:
 
*1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)''
 
*1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)''
 
*Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)''
 
*Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)''
 +
==History of changes in EMA indication==
 +
*1980-07-09: EURD
 
==History of changes in PMDA indication==
 
==History of changes in PMDA indication==
 
*2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy.
 
*2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy.
Line 199: Line 201:
  
 
[[Category:FDA approved in 1983]]
 
[[Category:FDA approved in 1983]]
 +
[[Category:EMA approved in 1980]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Revision as of 13:30, 13 June 2023

General information

Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1983-11-10: Initial FDA approval for refractory testicular tumors. (No supporting studies are cited)
  • Uncertain date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment. (Based on Hainsworth et al. 1995)

History of changes in EMA indication

  • 1980-07-09: EURD

History of changes in PMDA indication

  • 2012-02-22: New additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy.
  • 2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.

Also known as

  • Code names: VP-16, VP-TEC, VP 16213
  • Generic name: etoposide phosphate
  • Brand names:
Synonyms
Aside Beposid Bioposide Celltop Citodox Epocin Eposid Eposide
Eposido Eposin Epsidox ETO Etocris Etomedac Etonolver Etopofos
Etopophos Etopos Etoposid Etoposido Etopoxan Etopul Etosid Etosin
Eunades CS Euvaxon Exitop Fytop Fytosid Labimion Lastet Lastet S
Neoplaxol Nexvep Onkoposid Optasid Percas Posid Posidon Posyd
Riboposid Sintopozid Toposar Toposide Toposin Topresid Tosuben Vepefos
Vepesid Vepeside Vepsid Vepside

References

  1. ↑ 1.0 1.1 1.2 Etoposide (Vepesid) package insert
  2. ↑ Etoposide (Vepesid) package insert (locally hosted backup)
  3. ↑ Etoposide (Vepesid) patient drug information (Chemocare)
  4. ↑ Etoposide (Vepesid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Etoposide_(Vepesid)&oldid=73382"